Albireo Pharma Inc
ALBO
ALBO was delisted on the 2nd of March, 2023.
22 hedge funds and large institutions have $54.4M invested in Albireo Pharma Inc in 2017 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 6 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
9% more capital invested
Capital invested by funds: $50M → $54.4M (+$4.38M)
8% less funds holding
Funds holding: 24 → 22 (-2)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.08M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.57M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$126K |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$119K |
| 5 |
BlackRock
New York
|
+$46.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$732K |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$573K |
| 3 |
Renaissance Technologies
New York
|
-$236K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$204K |
| 5 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
-$49K |
ALBO Hedge Fund Activity: Q3 2017 in Review
22 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q3 2017, worth a combined $54.4M — up 8.8% from $50M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ALBO and 4 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 6 added.
The largest buyer was Point72 Asset Management, adding an estimated $4.08M. The largest seller was Sectoral Asset Management, cutting an estimated $732K.
- 22 institutional investors held Albireo Pharma Inc (ALBO) as of Q3 2017, down from 24 in Q2 2017.
- Funds reported $54.4M of Albireo Pharma Inc stock for Q3 2017, up 8.8% quarter-over-quarter.
- 4 funds opened new Albireo Pharma Inc positions in Q3 2017 and 6 closed out, a net change of -2 holders.
- The largest Albireo Pharma Inc buyer in Q3 2017 was Point72 Asset Management, an estimated $4.08M added.
- The largest Albireo Pharma Inc seller in Q3 2017 was Sectoral Asset Management, an estimated $732K sold.
Based on aggregated 13F filings for Q3 2017.